Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations ... competing drugs Ozempic and Wegovy ...

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug ... beat analysts’ expectations of $2.7 billion, according to a consensus estimate from FactSet (FDS). Sales of Ozempic during ...

Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy ... a disappointment compared to expectations in terms of absolute weight loss, but what we showed was ...

Sales of the company's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth ... while sales of diabetes drug Ozempic rose 12% on year to 33.85 billion kroner, compared ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn't its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations ... its next-generation weight loss drugs CagriSema ...